JNJ 64304500Alternative Names: JNJ 64304500 AAA; JNJ-64304500
Latest Information Update: 27 Dec 2016
At a glance
- Originator Janssen
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease
Most Recent Events
- 21 Dec 2016 Janssen Pharmaceutical plans a phase I trial in Healthy volunteers in Japan (SC) (NCT03002025).
- 11 Nov 2016 Phase-II clinical trials in Crohn's disease in Hungary (SC) (EudraCT2016-000634-21)
- 05 Aug 2016 Janssen plans a phase II trial for Crohn's disease in United Kingdom (NCT02877134, UKCRN30718)